Valuation: Axsome Therapeutics, Inc.

Market Cap 8.82B 7.88B 7.33B 6.66B 12.58B 853B 12.64B 88.18B 34.55B 435B 33.11B 32.39B 1,396B P/E 2026 *
-61.4x
P/E 2027 * 38x
Enterprise Value 8.67B 7.74B 7.2B 6.55B 12.37B 839B 12.43B 86.7B 33.97B 428B 32.56B 31.85B 1,373B EV / Sales 2026 *
9.01x
EV / Sales 2027 * 5.44x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-1.02%
1 week-6.08%
Current month-8.70%
1 month-20.26%
3 months-27.99%
6 months-5.48%
Current year-7.82%
1 week 166.12
Extreme 166.12
179.7
1 month 166.12
Extreme 166.12
223.29
Current year 152.28
Extreme 152.28
260.19
1 year 119.2
Extreme 119.2
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 12/01/2012
Director of Finance/CFO 51 16/05/2018
Chief Operating Officer 42 01/04/2014
Director TitleAgeSince
Chairman 57 12/01/2012
Director/Board Member 64 01/12/2014
Director/Board Member 58 01/12/2014
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26 Exercice

Chief Operating Officer

30,000 0.0573%
6/8/26 Exercice

Chief Executive Officer

13,980 0.0272%
1/7/26 Exercice

Chief Executive Officer

148,998 0.2895%
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-6.08%+38.32%+138.59% 8.82B
+0.83%+3.19%+41.49%+103.56% 1,051B
+1.93%+2.11%+37.08%+65.09% 630B
+1.49%+5.19%+19.94%+85.69% 489B
+2.26%+0.90%+69.32%+40.53% 359B
+1.45%+3.50%+23.29%+41.62% 344B
+1.17%+2.37%+13.47%+33.64% 272B
+0.89%+1.08%-6.13%+9.29% 246B
+1.82%+2.94%+42.99%+52.95% 224B
+2.77%+4.44%+29.01%+98.99% 187B
Average +1.36%+1.67%+30.88%+66.99% 381.25B
Weighted average by Cap. +1.46%+2.42%+33.37%+69.17%

Financials

2026 *2027 *
Net sales 963M 860M 800M 728M 1.37B 93.18B 1.38B 9.63B 3.77B 47.5B 3.62B 3.54B 152B 1.54B 1.38B 1.28B 1.17B 2.2B 150B 2.21B 15.45B 6.05B 76.22B 5.8B 5.67B 245B
Net income -144M -129M -120M -109M -206M -13.96B -207M -1.44B -565M -7.12B -542M -530M -22.84B 244M 218M 203M 184M 348M 23.59B 349M 2.44B 955M 12.03B 915M 895M 38.6B
Net Debt -148M -132M -123M -112M -211M -14.29B -212M -1.48B -578M -7.28B -554M -542M -23.37B -421M -376M -350M -318M -601M -40.74B -603M -4.21B -1.65B -20.77B -1.58B -1.55B -66.66B
Projected Income Statement - Annual - Axsome Therapeutics, Inc.
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
09/10/26 USD 168.35 -1.02% 894,518
08/10/26 USD 170.08 -1.67% 1,073,755
07/10/26 USD 172.97 -0.79% 887,361
06/10/26 USD 174.34 -1.55% 1,367,835
05/10/26 USD 177.08 -1.21% 858,894
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Axsome Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
168.35USD
Average target price
283.63USD
Spread / Average Target
+68.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Axsome Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AXSM Stock